Semaglutide and tirzepatide prescriptions for obesity are influenced by race, gender, social vulnerability, and urbanicity, with disparities in access and utilization. Despite increased ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...

Between 2021 and 2023, prescriptions of tirzepatide, semaglutide (Novo Nordisk), and sodium-glucose cotransporter 2 (SGLT2) inhibitors for people with T2D increased dramatically, while the use of ...

Semaglutide 2.0 mg was the most initiated medication (34.0%) vs 16.1% who initiated tirzepatide. Any use of tirzepatide jumped to 12.3% of all GLM use by December 2023, while SGLT2 inhibitor and ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

About The Study: Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of ...

Sharp increases were seen in dispensations of tirzepatide (0.0 to 40.6%) and semaglutide (2.4 mg; 0.0 to 32.2%) among adults without diabetes but prescribed WLMs; the most frequently dispensed WLM ...

Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide or tirzepatide, pursuant to a prescription. A shortage of ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Tirzepatide, a dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist, and semaglutide, a GLP-1RA, are used to treat diabetes. While both medications mimic the natural hormone ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

PINE BELT, Miss. (WDAM) - Mississippi Attorney General Lynn Fitch is warning Mississippians of unapproved and compounded weight loss drugs. Weight loss drugs have been on the rise in the last few ...